Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).

Thomas J SferraTomas MertaMichael Noel NeelyClaudia Murta de OliveiraAlvaro LassalettaClaudia Fortuny GuaschMary Beth DorrGregory WinchellFeng-Hsiu SuSarah PerkoDoreen FernslerHetty WaskinStephen R Holden

Published in: Journal of the Pediatric Infectious Diseases Society (2023)

NCT03182907 at ClinicalTrials.gov.

Keyphrases

double blind
clostridium difficile
clinical trial
placebo controlled
randomized controlled trial
silver nanoparticles
phase iii
phase ii
replacement therapy
open label
smoking cessation